ReviewTurkish journal of urology2017
Biparametric MRI of the prostate.
Review in Turkish journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Toward Autonomous Prostate Cancer Clinical Significance Determination from Spectral/Statistics Features in Bi-Parametric MRI.Cancers · 2026Article
- Multiparametric MRI findings, PI-RADS scores, and gleason scores in prostate cancer patients at Kumasi, Ghana: a cross-sectional analysis.BMC medical imaging · 2026Article
- Comparing and Combining Artificial Intelligence and Spectral/Statistical Approaches for Elevating Prostate Cancer Assessment in a Biparametric MRI: A Pilot Study.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Could Biparametric MRI Replace Multiparametric MRI in the Management of Prostate Cancer?Life (Basel, Switzerland) · 2023Review
- Performance variability of radiomics machine learning models for the detection of clinically significant prostate cancer in heterogeneous MRI datasets.Quantitative imaging in medicine and surgery · 2022Article
- Biparametric MR signal characteristics can predict histopathological measures of prostate cancer.European radiology · 2022Article
- Lesion Volume in a Bi- or Multivariate Prediction Model for the Management of PI-RADS v2.1 Score 3 Category Lesions.Turkish journal of urology · 2022Article
- Diagnostic value of integratedProstate international · 2022Article
- Current Value of Biparametric Prostate MRI with Machine-Learning or Deep-Learning in the Detection, Grading, and Characterization of Prostate Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2022Review
- MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy.Turkish journal of urology · 2021Article
- Simplified PI-RADS (S-PI-RADS) for biparametric MRI to detect and manage prostate cancer: What urologists need to know.Turkish journal of urology · 2021Article
- Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature.Contrast media & molecular imaging · 2021Article
- Active surveillance in prostate cancer management: where do we stand now?Archives of medical science : AMS · 2021Article
- Review
- Round table: arguments in supporting abbreviated or biparametric MRI of the prostate protocol.Abdominal radiology (New York) · 2020Review
- Biparametric magnetic resonance imaging in the surveillance of testicular tumors following radical orchiectomy.Turkish journal of urology · 2020Review
- Locally advanced prostate cancer imaging findings and implications for treatment from the surgical perspective.Abdominal radiology (New York) · 2020Review
- PSA/biparametric MRI: An accurate potential diagnostic approach for detection and management of local recurrence after radical prostatectomy.Turkish journal of urology · 2020Article
- Multiparametric MRI for prostate cancer diagnosis: current status and future directions.Nature reviews. Urology · 2020Review
Corrections and comments
- Erratum issuedErratum.2018
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biparametric Magnetic Resonance Imaging (bpMRI) of the prostate combining both morphologic T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) is emerging as an alternative to multiparametric MRI (mpMRI) to detect, to localize and to guide prostatic targeted biopsy in patients with suspicious prostate cancer (PCa). BpMRI overcomes some limitations of mpMRI such as the costs, the time required to perform the study, the use of gadolinium-based contrast agents and the lack of a guidance for management of score 3 lesions equivocal for significant PCa. In our experience the optimal and similar clinical results of the bpMRI in comparison to mpMRI are essentially related to the DWI that we consider the dominant sequence for detection suspicious PCa both in transition and in peripheral zone. In clinical practice, the adoption of bpMRI standardized scoring system, indicating the likelihood to diagnose a clinically significant PCa and establishing the management of each suspicious category (from 1 to 4), could represent the rationale to simplify and to improve the current interpretation of mpMRI based on Prostate Imaging and Reporting Archiving Data System version 2 (PI-RADS v2). In this review article we report and describe the current knowledge about bpMRI in the detection of suspicious PCa and a simplified PI-RADS based on bpMRI for management of each suspicious PCa categories to facilitate the communication between radiologists and urologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.